- Home
- OPTN vs HOWL Comparison
OPTN vs HOWL Comparison
Compare OPTN & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- HOWL
- Stock Information
- Founded
- OPTN 2010
- HOWL 2017
- Country
- OPTN United States
- HOWL United States
- Employees
- OPTN N/A
- HOWL N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- OPTN Health Care
- HOWL Health Care
- Exchange
- OPTN Nasdaq
- HOWL Nasdaq
- Market Cap
- OPTN 78.4M
- HOWL 87.4M
- IPO Year
- OPTN 2017
- HOWL 2021
- Fundamental
- Price
- OPTN $0.45
- HOWL $1.62
- Analyst Decision
- OPTN Strong Buy
- HOWL Strong Buy
- Analyst Count
- OPTN 3
- HOWL 2
- Target Price
- OPTN $3.00
- HOWL $13.50
- AVG Volume (30 Days)
- OPTN 1.2M
- HOWL 411.3K
- Earning Date
- OPTN 11-12-2024
- HOWL 11-07-2024
- Dividend Yield
- OPTN N/A
- HOWL N/A
- EPS Growth
- OPTN N/A
- HOWL N/A
- EPS
- OPTN N/A
- HOWL N/A
- Revenue
- OPTN $75,672,000.00
- HOWL $3,386,000.00
- Revenue This Year
- OPTN $13.42
- HOWL N/A
- Revenue Next Year
- OPTN $52.99
- HOWL $34.17
- P/E Ratio
- OPTN N/A
- HOWL N/A
- Revenue Growth
- OPTN 5.13
- HOWL N/A
- 52 Week Low
- OPTN $0.32
- HOWL $1.58
- 52 Week High
- OPTN $2.10
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- OPTN 39.55
- HOWL 34.79
- Support Level
- OPTN $0.42
- HOWL $1.62
- Resistance Level
- OPTN $0.57
- HOWL $1.72
- Average True Range (ATR)
- OPTN 0.05
- HOWL 0.12
- MACD
- OPTN 0.00
- HOWL -0.01
- Stochastic Oscillator
- OPTN 26.39
- HOWL 6.12
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.